Serum proteomics identify biomarkers and pathogenesis of portopulmonary hypertension diagnosed based on echocardiography
Authors:
Open Access
- 1 July 2025
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-12
Abstract
Portal pulmonary hypertension (PoPH), a severe complication of portal hypertension (PHTN), is marked by elevated pulmonary arterial pressure, but its pathophysiological mechanisms are unclear. This study used proteomics to identify differentially expressed proteins (DEPs) and genes in Patients with PoPH compared to those with PHTN and healthy controls (HC), aiming to uncover potential biomarkers for diagnosis and treatment. Patients with liver cirrhosis and PHTN, admitted between January 2023 and May 2024, were classified into PoPH and non-PoPH (PHTN) groups based on echocardiography. Serum from 12 PoPH, 12 PHTN, and 6 HC was analyzed using data-independent acquisition (DIA) proteomics to identify DEPs. Protein-protein interaction (PPI) networks identified key DEPs, and ELISA was performed for biomarker validation. Compared to HC, 374 proteins were upregulated and 115 downregulated in PoPH, while 18 were upregulated and 38 downregulated in PHTN. KEGG and GO analyses linked DEPs to immune response, metabolism, and cell signaling. Thirty-five proteins distinguish PoPH from HC and PHTN. Vitronectin (VTN, P04004) was correlated with RDW (R = -0.56, P < 0.01) and PLT (R = 0.52, P < 0.01). ELISA confirmed lower VTN levels in PoPH (P < 0.05). This study identified 35 serum proteins involved in PoPH, with VTN as a potential biomarker for distinguishing PoPH from PHTN and HC. Further research is needed to explore these findings.Keywords
Funding Information
- Foundation of Science and Technology Commission of Jilin Province (Grants No. 20220203126SF, Grants No. 20220203126SF, Grants No. 20220203126SF, Grants No. 20220203126SF, Grants No. 20220203126SF, Grants No. 20220203126SF, Grants No. 20220203126SF)
This publication has 44 references indexed in Scilit:
- The recombinant disintegrin, jarastatin, inhibits platelet adhesion and endothelial cell migrationToxicon, 2022
- Baveno VII – Renewing consensus in portal hypertensionJournal of Hepatology, 2022
- Hepatopulmonary Syndrome and Portopulmonary Hypertension: The Pulmonary Vascular Enigmas of Liver DiseaseClinical Liver Disease, 2020
- Thrombocytopenia independently predicts death in idiopathic PAHHeart & Lung, 2019
- Survival in portopulmonary hypertension: Outcomes of the United Kingdom National Pulmonary Arterial Hypertension RegistryThe Journal of Heart and Lung Transplantation, 2017
- Spike‐in SILAC proteomic approach reveals the vitronectin as an early molecular signature of liver fibrosis in hepatitis C infections with hepatic iron overloadProteomics, 2014
- Fibronectin and vitronectin induce AP-1-mediated matrix metalloproteinase-9 expression through integrin α5β1/αvβ3-dependent Akt, ERK and JNK signaling pathways in human umbilical vein endothelial cellsCellular Signalling, 2011
- Role of Vitronectin and Its Receptors in Haemostasis and Vascular RemodelingThrombosis Research, 1998
- Distribution of vitronectin in plasma and liver tissue: Relationship to chronic liver diseaseHepatology, 1994
- Pulmonary hypertension complicating portal hypertension: Prevalence and relation to splanchnic hemodynamicsGastroenterology, 1991